genOway | ULTIMATE PREDICTABILITY

genO-panhCD3 (scan or click)

HUMANIZED genO-panhCD3 MOUSE MODEL

genO-panhCD3 (humanized ε, δ and γ chains - hCD3edg) immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.


APPLICATIONS

genO-panhCD3 drives advances across **immuno-oncology** and **autoimmunity**, enabling the following applications:

- ☑ Assess the **efficacy of T-cell engagers** (TCE)
  - Perform tumor inhibition assays
  - Test TCE for inhibition of autoimmune diseases
- ☑ **Evaluate the safety** of therapeutics, such as inducing cytokine release syndrome (CRS) via treatment with anti-CD3 antibodies

THEY CHOSE THIS MODEL

AstraZeneca · Seattle Children's Hospital · Research · Foundation · zymeworks · IRCCS Istituto di Ricerche Farmacologiche Mario Negri



MODEL FEATURES

- ☑ Physiological expression of humanized CD3edg (ε, δ and γ)
- ☑ Lack of expression of the murine target gene
- ☑ Fully functional, and with unchanged homeostasis, mouse immune system
- ☑ Functional CD3/TCR interaction
- ☑ Functional T/B-cell cooperation
- ☑ Available on different genetic backgrounds C57BL/6 & BALB/c

INDS WITH THE MODEL

AstraZeneca **Molecule tested: AZD5863**

zymeworks **Molecule tested: ZW171**

ORDERS, DELIVERY & CARE

- ☑ Orders are made directly with genOway; breeding, housing and delivery are outsourced
- ☑ Breeding facilities in the US and Europe through our trusted partners:

TACONIC BIOSCIENCES · charles river


- ☑ Quick, compliant, and reliable door-to-door delivery worldwide at your facility or at the CRO of your choice
- ☑ Models with certified **SOPF** health status from **AAALAC-accredited** and **PHS-assured** professional breeders

genOway | ULTIMATE PREDICTABILITY


genO-panhCD3 (scan or click)

SELECTED VALIDATION DATA


More data available on our website or upon request




hCD3 expression pattern recapitulates that of mCD3



Anti-CD3 induces T-cell activation – TCR/CD3 complex is functional



OKT3 induces cytokine release and related clinical signs in genO-panhCD3 mice



AZD5863 improves tumor growth inhibition when combined with anti-PD-1 or with CAPOX + anti-PD-1 in genO-panhCD3 mice

AstraZeneca

KEY PUBLICATIONS

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI · IRCCS

Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases
Perico L., 2024 - Frontiers in Immunology

AstraZeneca

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release
Gaspar M., 2025 - J Immunother Cancer

RELATED MODELS

MICE		CELLS	
genO-panhCD3/hPD-1/hPD-L1	genO-panhCD3/hSA/hFcRn	genO-EL4-hCD19-LZ	genO-MC38-hPD-L1-hFAP-LZ
genO-panhCD3/hPD-1	genO-panhCD3/hCD137	genO-EL4-hCD20-LZ	genO-MC38-hFAP-LZ
genO-panhCD3/hFcγR	genO-panhCD3/ hIgG1/hIgκ	genO-MC38-hEpCAM-LZ	genO-MC38-hPD-L1
genO-panhCD3/hCD28	... and more	genO-MC38-hPD-L1-hHER2	genO-MC38-hPD-L1-LZ

For more information

Visit the genO-panhCD3 page

For further inquiries

Contact Us